Holen Sie sich die Stockscreener-App
14.06
1.44%
0.20
Schlusskurs vom Vortag:
$13.86
Offen:
$13.93
24-Stunden-Volumen:
1.45M
Relative Volume:
0.80
Marktkapitalisierung:
$44.58B
Einnahmen:
$30.25B
Nettoeinkommen (Verlust:
$1.37B
KGV:
33.03
EPS:
0.4257
Netto-Cashflow:
$5.08B
1W Leistung:
+3.84%
1M Leistung:
+7.33%
6M Leistung:
-5.89%
1J Leistung:
-4.61%
1-Tages-Spanne:
$13.93
$14.10
1-Wochen-Bereich:
$13.66
$14.10
52-Wochen-Spanne:
$12.57
$15.08
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Vergleichen Sie TAK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-07-19 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-10-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Eingeleitet | Cowen | Market Perform |
| 2019-08-15 | Herabstufung | Daiwa Securities | Outperform → Neutral |
Alle ansehen
Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten
Yaqrit strengthens board and senior management ahead of multi-prong clinical push in advanced liver disease - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… - MSN
TAK vs. DSNKY: Which Stock Is the Better Value Option? - Nasdaq
Ex-Intern Becomes Billionaire in Australia Pharmacy Merger - MSN
IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, - openPR
IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, - openPR
Procter & Gamble Co (PG) expanding its growth trajectory ahead - SETE News
Prepare Yourself for Liftoff: AMKOR Technology Inc (AMKR) - SETE News
Takeda Pharmaceutical Co ADR [TAK] President, Plasma-Derived Ther makes an insider purchase of 19,073 shares worth 0.28 million. – Knox Daily - Knox Daily
Advanced Drainage Systems Inc [WMS] Records 50-Day SMA of $122.78 - Knox Daily
GFL Shares Experience Surge in Value - Knox Daily
UBS Group AG [UBS] Shares Rise 2.39 % on Thursday - Knox Daily
Takeda Pharmaceutical Co ADR (TAK)’s stock price range in the last year - US Post News
Inmode Ltd (INMD) Stock Price and Analyst Predictions - The News Heater
Recent Insider Activity Could Benefit Wabash National Corp (WNC) - Knox Daily
Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - Knox Daily
Japan’s Takeda launches innovation centre in Bengaluru; to hire 750 in 2025 - Deccan Herald
Weekly Upgrades and Downgrades - InvestorPlace
Amgen stock price formed a death cross: will it rebound in 2025? - MSN
Saudi Arabia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
USFDA gives tentative approval to Lupin’s generic formulation to treat type 2 diabetes - The Financial Express
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow
Things To Consider Before You Buy Takeda Pharmaceutical Co ADR (NYSE: TAK) - Stocks Register
Capital One Financial Corp (NYSE: COF): Overvalued In Comparison To Others? - Stocks Register
Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - MSN
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow
Australia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Denmark Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Italy Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
UK Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
South Africa Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):